Details of the Drug Combination

General Information of Drug Combination (ID: DCXT5OW)

Drug Combination Name
Acalabrutinib Acalabrutinib
Indication
Disease Entry Status REF
Pharmacokinetics Phase 1 [1]
Component Drugs Acalabrutinib   DM7GCVW Acalabrutinib   DM7GCVW
N.A. N.A.
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Acalabrutinib
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [2]
Mantle cell lymphoma 2A85.5 Approved [3]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Acalabrutinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [3]
HUMAN bruton tyrosine kinase (BTK) TTOWPER BTK_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Acalabrutinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Acalabrutinib Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Affects Expression [8]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [8]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Metabolism [9]
------------------------------------------------------------------------------------
Indication(s) of Acalabrutinib
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [2]
Mantle cell lymphoma 2A85.5 Approved [3]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Acalabrutinib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase BTK (ATK) TTGM6VW BTK_HUMAN Inhibitor [3]
HUMAN bruton tyrosine kinase (BTK) TTOWPER BTK_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Acalabrutinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Acalabrutinib Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Affects Expression [8]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [8]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Metabolism [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04435483) A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 210259
3 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT04346199) Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.. U.S. National Institutes of Health.
6 AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
7 FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
8 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
9 Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. Chem Biol Interact. 2021 Aug 25;345:109559. doi: 10.1016/j.cbi.2021.109559. Epub 2021 Jun 18.